Baylor College of Medicine

Study to Evaluate ARO-APOC3 in Adults with Severe Hypertriglyceridemia (H-49749)



The purpose of this study is to evaluate the efficacy and safety of an investigational drug in patients with severe hypertriglyceridemia. Participants will receive two subcutaneous injections of drug or placebo during the 48-week study. Eligibility requirements include triglycerides 500 mg/dL or higher on more than one occasion, medical history of clinical atherosclerotic cardiovascular disease or elevated 10-year cardiovascular disease risk, no recent pancreatitis or major surgery, no current diagnosis of nephrotic syndrome, and no genetically confirmed diagnosis of familial chylomicronemia syndrome.

IRB: H-49749




Back to topback-to-top